eligibility_summary
Adults (≥18) with confirmed neuroendocrine neoplasms or ACC, locally advanced/metastatic, measurable (RECIST 1.1), after standard therapy, refractory/intolerant, ECOG ≤2, adequate organ function, stable brain mets ok. Exclude recent anticancer therapy/surgery, herbal use, wound dehiscence/effusions, active infection/bleeding, allergy to similar drugs, active autoimmune disease, QTcF ≥480 ms, another active cancer, live vaccine <30d, pregnancy, uncontrolled illness.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: ADCT-701, an antibody–drug conjugate (ADC). It is a humanized monoclonal antibody targeting DLK1 (Delta-like 1), a non-canonical Notch ligand, linked to a cytotoxic payload. Mechanism: ADCT-701 binds DLK1 on tumor cells, is internalized, and releases its payload to induce targeted tumor cell kill, engagement of DLK1 addresses a pathway implicated in tumor cell plasticity and chemoresistance. Targets: DLK1-expressing neuroendocrine neoplasms (NETs/NECs) and adrenocortical carcinoma. Pathways/cells: DLK1–Notch signaling axis on neuroendocrine lineage tumor cells (including ACC), with expression reported in SCLC-like NECs, neuroblastoma, pheochromocytoma, and paraganglioma. Study: First-in-human Phase I, single-arm, 3+3 dose escalation, IV Day 1 of 21-day cycles, to define MTD/optimal dose.